Neuphoria Therapeutics Inc.
NEUP
NASDAQ·Healthcare·Biotechnology·Mkt cap $20.4M
$3.77
▲ +0.27%
P/E
—
Mkt Cap
$20.4M
52-Wk Range
$3.19–$21.40
52-Week Range
$3.19 - $21.40
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 71.0% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Specialized focus on neuropsychiatric indications with high unmet medical needs
- Early-stage positioning allowing for novel mechanism exploration
- Access to emerging biotechnology research and development platforms
- Strategic location in biotech hub near leading research institutions
Bear Case
1 risk
- Low volatility (beta 0.8).
Growth
Stable outlook
Advancement of clinical-stage candidates through development pipeline
Value
Deep value opportunity - significant discount to sector peers
Momentum
Weak
-19.3% over 3m
Quality
Excellent
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying NEUP right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Oct 5, 2026
SEP 2, 2026
Reported EPS of -$0.56 vs -$0.56 consensus (0.0% surprise).
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
0.0%
Revenue trend · last 8Q
—
—
—
—
—
—
-100%
-100%
Q4 24
Q1 24
Q2 24
Q3 25
Q4 25
Q1 25
Q2 25
Q3 26
$0
$0
$1.1M
$23.9M
-$15.7M
$0
$0
$0
Margins · last 8Q
Gross
—
Operating
—
Profit
—
Wall Street consensus
1 analyst · 0% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
0%
Hold
100%
Sell
0%
Median Price Target
—
Latest: HC Wainwright · May 15, 2026
vs Industry
How NEUP stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.